IMAC Holdings Inc. Announces Exciting Advancement in Precision Oncology
IMAC Holdings, Inc. is thrilled to share the launch of its innovative subsidiary, Ignite Proteomics LLC, which focuses on precision oncology solutions. Ignite Proteomics has introduced a state-of-the-art assay that leverages Reverse Phase Protein Array (RPPA) technology to enhance decision-making in breast cancer treatment. This significant milestone comes after IMAC Holdings strategically acquired essential assets from Theralink Technologies, bolstering its strength in the fast-changing healthcare sector.
Revolutionizing Cancer Treatment with Cutting-Edge Technology
Ignite Proteomics is distinguished by its exclusive offering: the only commercially available and clinically validated assay capable of assessing both protein expression and activation levels in breast tumors. This groundbreaking method is a pivotal advancement for understanding how well targeted cancer therapies work. The practical implications of Ignite’s innovative proteomic assay are highlighted through a compelling case study of a 57-year-old woman battling metastatic triple-negative breast cancer (TNBC).
Case Study: Inspiring Treatment Response
This patient had tried several treatment options, including chemotherapy and targeted therapy, but unfortunately continued to see disease progression in critical areas, such as the brain and liver. By participating in a clinical trial at Inova Schar Cancer Institute, she had a chance to compare the effectiveness of Ignite’s RPPA technology against existing next-generation sequencing (NGS) assays. Importantly, the RPPA assay uncovered the expression and activation of HER2, an essential protein that had been missed in earlier analyses.
Successful Treatment Outcomes
The patient was promptly started on trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that depends on HER2 expression for its effectiveness. After nine treatment cycles, the outcomes were remarkable: the patient showed no measurable disease, indicating a complete response to the therapy.
Leadership Insight: Focus on Patient-Centric Care
Faith Zaslavsky, the CEO of IMAC Holdings and Ignite Proteomics, expressed her enthusiasm for this development, stating, "The RPPA technology and our innovative proteomics assay mark a significant breakthrough in managing breast cancer. They provide crucial insights, allowing us to personalize treatments with greater precision and effectiveness. The success of this case study underlines the potential of our assay to meaningfully improve patient outcomes."
About IMAC Holdings, Inc.
IMAC Holdings, Inc. is fully committed to pioneering healthcare solutions that significantly enhance patient care. With a focus on strategic acquisitions and the creation of groundbreaking technologies, IMAC Holdings remains a vital force in promoting precision medicine.
About Ignite Proteomics
Ignite Proteomics LLC, a key subsidiary of IMAC Holdings, specializes in advanced RPPA technology for cancer diagnostics. As the sole provider of a CLIA-accredited RPPA assay for breast cancer, Ignite Proteomics exemplifies excellence in protein-focused testing and personalized oncology solutions.
Frequently Asked Questions
What is Ignite Proteomics?
Ignite Proteomics is a subsidiary of IMAC Holdings that specializes in developing advanced RPPA technology for precision cancer diagnostics.
How does the new assay improve breast cancer treatment?
This assay enables clinicians to assess protein expression and activation levels, offering clearer insights into treatment effectiveness for breast cancer therapies.
What makes RPPA technology unique?
RPPA technology is distinctive because it measures both the expression and activation levels of proteins, creating a comprehensive profile that enhances treatment customization.
What was the outcome of the case study?
In the case study, the patient experienced a complete response to therapy after previously unsuccessful treatments, underscoring the effectiveness of the assay.
Who leads IMAC Holdings and Ignite Proteomics?
Faith Zaslavsky is the CEO of both IMAC Holdings and Ignite Proteomics, guiding initiatives that focus on innovative healthcare solutions.
